Phase I/II study on the safety and efficacy of repeated administration of FIT039 transdermal patch for verrucas caused by human papilloma-virus - Evaluation on the safety and efficacy of repeated administration of FIT039 for verrucas

Department of Dermatology, Kyoto University Hospital0 个研究点目标入组 44 人开始时间: 2017年11月1日最近更新: 2023年10月17日

适应症

试验速览

暂无简介。

•Men and women who meet the following criteria are excluded: 1. Allergic to transdermal patches. 2. Having one of the following complications: serious heart disease, gastrointestinal disease, liver disease, kidney disease, systemic skin disorders with lesions at the target verruca vulgaris, uncontrolled diabetes mellitus, infectious diseases requiring continuous treatment by injection or oral application of medical agents, or diseases requiring continuous systemic administration of immunosuppressants or steroids. 3. Having an active malignancy, excluding conditions such as, adequately treated basal cell carcinoma, intraepithelial carcinoma, or superficial bladder carcinoma, or a malignant tumor not showing metastasis or recurrence for 5 years or more from the end of treatment. 4. Having other verruca vulgaris warts within 1 cm from the target wart. 5. Having been treated with cryotherapy for the target wart within 4 weeks prior to the acquisition of written consent. 6. Taking general antiviral drugs within 4 weeks prior to the acquisition of the written consent. 7. Participating in other trials within 4 weeks prior to the acquisition of the written consent.

发起方

Department of Dermatology, Kyoto University Hospital